Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | GPR183 | P32249 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11838494 | 0.86 | SIGMAR1 (0.53) | ALDH1A1FAAHGPR183HRH3 | |
| SCHEMBL1975609 | 0.86 | CYP2D6 (0.57) | ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL10732688 | 0.84 | POLB (0.58) | ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2088271 | 0.84 | POLB (0.58) | ALDH1A1MEN1KMT2A | |
| SCHEMBL11888827 | 0.84 | POLB (0.56) | ALDH1A1FAAHGPR183HRH3 | |
| SCHEMBL11888852 | 0.83 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2AATMFAAH | |
| SCHEMBL11888874 | 0.83 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2AFAAHGPR183 | |
| SCHEMBL11888930 | 0.81 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2AFAAHGPR183 | |
| Sulfuric Acid SCHEMBL11835144 | 0.81 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2AFAAHGPR183 | |
| Sulfuric Acid SCHEMBL11839097 | 0.81 | MAPK1 (0.56) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480532-B1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | claimed |
| EP-2480532-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | claimed |
| CN-102471265-A | Piperidine derivatives and their use for the treatment of obesity, diabetes, dyslipidemia and atherosclerosis | HOFFMANN LA ROCHE | 2012-05-23 | — | — | CN | claimed |
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-03 | — | — | US | claimed |
| EP-2480532-B1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-8399676-B2 | Piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2480532-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| CN-102471265-A | Piperidine derivatives and their use for the treatment of obesity, diabetes, dyslipidemia and atherosclerosis | HOFFMANN LA ROCHE | 2012-05-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | ADRA1D, ADORA1, H1-0 | ALDH1A1 45/4885MEN1 2306/4885KMT2A 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.